glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies The predicted impact of GLP‐1

GLP-1 agonists are great for you if you: Are between 18 and 65 years BMI greater than or equal to 30 Have type 2 Diabetes mellitus Trying to lose weight The following will make you ineligible for this treatment: History of pancreatitis History of thyroid disease Pregnancy and breastfeeding Kidney problems Gastroparesis Similar & Related Procedures Dipeptidyl Peptidase-4 (DPP-4) inhibitors : This medication prevents the breakdown of GLP-1/GIP agonists

Quick Reference: Injection site reactions: 15-25% (mild, resolve in 2-24 hours) Nausea: 5-10% (transient, first week) Dizziness: 3-7% (occasional, brief) Serious events: Zero documented in 100+ animal studies Typical dose: 250-500 mcg/day SubQ

Dulaglutide is distinguished by a positive safety record with rare occurrences of serious adverse effects

M., Duran, M., and Wijburg, F

Nu bn ang dng Magie B6 theo toa ca bc s hoc theo hng dn ca mt chuyn gia sc khe, hy tun theo cc ch dn